Drug Trial Radar · NCT07631325
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jul 31, 2028
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- John KirkwoodAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Glycyx MOR Inc.
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.
Conditions
- Unresectable Cutaneous Melanoma
Interventions
AxelopranDrug
A peripherally restricted mu-opioid receptor antagonist (PAMORA) designed to mitigate the undesirable peripheral effects of opioids without compromising their central analgesic action.
NivolumabDrug
An immune checkpoint inhibitor that helps the immune system attack cancer cells by blocking PD-1 receptors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events Related to TreatmentTime frame: Up to 30 days post end of treatment
- Best objective response rate (BORR)Time frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.